Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.18 USD
+0.01 (0.85%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $1.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ACRS 1.18 +0.01(0.85%)
Will ACRS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ACRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACRS
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
ACRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
Other News for ACRS
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
H.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)
Aclaris Therapeutics: Hold Rating Amidst Clinical Uncertainty and Strategic Review
Aclaris Therapeutics GAAP EPS of -$0.15, revenue of $2.8M
Aclaris: Q2 Earnings Snapshot